The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 02, 2024

Filed:

Feb. 08, 2018
Applicant:

Dana-farber Cancer Institute, Inc., Boston, MA (US);

Inventors:

Dennis Buckley, Jamaica Plain, MA (US);

Georg Winter, Vienna, AT;

Andrew J. Phillips, Cambridge, MA (US);

Timothy P. Heffernan, Cambridge, MA (US);

James Bradner, Weston, MA (US);

Justin Roberts, Cambridge, MA (US);

Behnam Nabet, Boston, MA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/90 (2006.01); A61K 35/12 (2015.01); A61K 35/407 (2015.01); A61K 38/46 (2006.01); A61K 47/55 (2017.01); A61K 48/00 (2006.01); C12N 9/10 (2006.01); C12N 9/22 (2006.01); C12N 9/90 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0058 (2013.01); A61K 35/407 (2013.01); A61K 38/465 (2013.01); A61K 48/0025 (2013.01); A61K 48/0083 (2013.01); C12N 9/104 (2013.01); C12N 9/22 (2013.01); C12N 9/90 (2013.01); C07K 2319/20 (2013.01); C07K 2319/95 (2013.01); C12Y 502/01008 (2013.01);
Abstract

The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.


Find Patent Forward Citations

Loading…